Aktis Oncology Inc.
Aktis Oncology Inc. (AKTS): 4 pipeline candidates · ~53 mo cash runway · 2 clinical trials. Updated within the last hour.
BioSniper Score
5-factor signal · derived from public data
52.5 months
D/E 0.14 · 0% dilution
Lead: Phase 1
4 candidates
N/A
9 buys · 0 sells (180d)
A transparent, data-derived signal for Aktis Oncology Inc.across cash runway, pipeline maturity & breadth, catalyst momentum and clinical/regulatory footprint. Each factor traces to tracked public filings — not an investment recommendation.
Key Financials
Market Cap
$1.2B
Cash
$372.8M
Quarterly Burn
$24.2M
Runway
52.5 mo
Revenue
$3.2M
Cash Runway vs Catalysts
Tracked catalysts land within the current projected cash runway.
Pipeline (4 candidates)
| Drug | Phase |
|---|---|
| [225ac]ac-aky-1189 | Phase 1 |
| [225ac]ac-aky-2519 | Phase 1 |
| [64cu]cu-aky-1189 | Phase 1 |
| [64cu]cu-aky-2519 | Phase 1 |
Institutional Holdings
Source: SEC Form 13F · as of Mar 2026Institutional holders
66
Total value held
$463.7M
| Holder | Shares | Value |
|---|---|---|
| mpm bioimpact llc | 4,835,872 | $86.5M |
| janus henderson group plc | 2,908,534 | $52.0M |
| wellington management group llp | 2,317,044 | $41.5M |
| blackrock, inc. | 2,112,127 | $37.8M |
| vanguard capital management llc | 1,667,826 | $29.8M |
| rtw investments, lp | 1,592,043 | $28.5M |
| ra capital management, l.p. | 1,503,084 | $26.9M |
| baker bros. advisors lp | 996,351 | $17.8M |
| octagon capital advisors lp | 960,847 | $17.2M |
| avidity partners management lp | 937,132 | $17.2M |
Showing top 10 of 66 institutional holders of Aktis Oncology Inc.. Sign up for the full 13F holder list and quarter-by-quarter ownership history.
Frequently asked questions
How many drug candidates are in Aktis Oncology Inc.'s pipeline?
Aktis Oncology Inc. (AKTS) has 4 pipeline candidates tracked by BioSniper across SEC filings and clinical trial registrations.
What is Aktis Oncology Inc.'s lead drug candidate?
Aktis Oncology Inc.'s most advanced tracked candidate is [225ac]ac-aky-1189 (Phase 1) for Urothelial Carcinoma Bladder.
What is Aktis Oncology Inc.'s cash runway?
Based on its most recent reported cash balance and quarterly burn rate, Aktis Oncology Inc. has approximately 52.5 months of cash runway.
What is Aktis Oncology Inc.'s market capitalization?
Aktis Oncology Inc.'s market capitalization is approximately $1.2B.
Who is the CEO of Aktis Oncology Inc.?
Dr. Matthew Roden Ph.D. is the chief executive officer of Aktis Oncology Inc. (AKTS).
Get the full picture on Aktis Oncology Inc.
Deep pipeline analysis, financial trends, AI-powered investment signals, and real-time catalyst alerts.